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OBJECTIVEdThe American Diabetes Association and the English NHS Diabetic Eye Screen-
ing Program recommend annual screening for diabetic retinopathy (DR) with referral to oph-
thalmology clinics of patients with sight-threatening DR (STDR). Using only longitudinal data
from retinal photographs in the population-based NHS Diabetic Eye Screening Program in
Gloucestershire, we developed a simple means to estimate risk of STDR.
RESEARCH DESIGN AND METHODSdFrom 2005, 14,554 patients with no DR or
mild nonproliferative DR only at two consecutive annual digital photographic screenings were
categorized by the presence of DR in neither, one, or both eyes at each screening and were
followed for a further median 2.8 years.
RESULTSdOf 7,246 with no DR at either screening, 120 progressed to STDR, equivalent to an
annual rate of 0.7%. Of 1,778 with no DR in either eye at ﬁrst screening and in one eye at second
screening, 80 progressed to STDR, equivalent to an annual rate of 1.9% and to a hazard ratio (HR)
of 2.9 (95%CI 2.2–3.8) compared with those with no DR. Of 1,159 with background DR in both
eyes at both screenings, 299 progressed to STDR equivalent to an annual rate of 11% and an HR
of 18.2 (14.7–22.5) compared with individuals with no DR.
CONCLUSIONSdCombining the results from 2 consecutive years of photographic screen-
ing enables estimation of the risk of future development of STDR. In countries with systematic
screening programs, these results could inform decisions about screening frequency.
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D iabetic retinopathy (DR) is a com-plication of diabetes that can lead toblindness. The American Diabetes
Association recommends (1) annual eye
examinations for all people with diabetes
mellitus (DM) and the English NHS Di-
abetic Eye Screening Program (2) recom-
mends annual screening for DR; both sets
of recommendations have the goal of re-
ferring people with sight-threatening DR
(STDR) to ophthalmologists for assess-
ment and treatment. Two recent studies
(3,4) have shown that since 1985, people
with diabetes have experienced lower
rates of progression to proliferative DR
and severe visual loss, probably reﬂecting
improvements in diabetes care. Apart
from the convenience of annual screening,
the rationale behind the recommendations
assumes that people should receive annual
screening regardless of their actual risk of
developing retinopathy. Most annual eye
examinations now include digital retinal
photographs to monitor the presence or
absence of any DR. There has been a debate
whether examinations are required yearly
for all people with diabetes, with James
et al. (5) reporting annual photographic
screening to be cost-effective, but Vijan
et al. (6) concluding that annual retinal
screening for all patients with type 2 diabe-
tes without previously detected retinopa-
thy may not be warranted on the basis of
cost-effectiveness and recommended
tailoring the frequency of screening to in-
dividual circumstances.
At the time that annual digital photo-
graphic screening was introduced in En-
gland in 2003, the Department of Health
reported ;1.4 million people known to
have diabetes; as of December 2011, the
prevalence reported (7) by screening serv-
ices is now 2.5 million. As the publically
funded health care system in the U.K. has
limited funds, this has led to challenges
providing retinal screening, a concern
shared by both developed and developing
nations as the number of people with
diabetes rises (8). In 2004, Kempen et al.
(9) reported that, among an estimated 10.2
million U.S. adults $40 years known to
have DM, the estimated crude prevalence
rates for retinopathy and vision-threatening
retinopathy were 40.3 and 8.2%, re-
spectively. In November 2011, the Inter-
national Diabetes Federation released
the 5th edition of the Diabetes Atlas (8),
which indicated that the number of people
living with diabetes in all age groups in the
U.S. had risen to 23.7 million, and the
number in the world is expected to rise
from 366 million in 2011 to 552 million
by 2030.
In order to more efﬁciently use limited
funds, extending the screening interval
from annually to longer than annually has
been proposed. Two sources of data have
been considered: 1) a retinal photograph
from one-time screening, and 2) a combi-
nation of clinical and demographic risk
factors. Decisions based on retinal photog-
raphy from a single visit, although sup-
ported by studies (10–12), were rejected
by the American Diabetes Association (1)
in 2002, which concluded that the annual
eye examination is still warranted, citing
that the evidence (12,13) was not general-
izable to the greater population of people
with diabetes and that it might lead to
patients not attending screening. Deter-
mining screening intervals using a combi-
nation of clinical and demographic risk
factors combinedwith recent photographic
screening results (14) is equally prob-
lematic, as the clinical information may
not be available, may be unreliable (e.g.,
reported duration of diabetes), and in
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some countries may not be collected (e.g.,
HbA1c).
In this study, we used longitudinal
data from the results from retinal photo-
graphic images from two annual screen-
ing episodes in the population-based
NHS Diabetic Eye Screening Program in
Gloucestershire, U.K., to evaluate the in-
cidence and time to recommended re-
ferral of potentially sight-threatening
retinopathy.
RESEARCH DESIGN AND
METHODSdThe patient population
from which our cohort was taken com-
prised 31,329 people with diabetes from
the Gloucestershire Diabetic Eye Screen-
ing Service who were screened for reti-
nopathy between the 4 January 2005 and
20 December 2010. Patients invited to
retinal screening include all people with
diabetes (type 1 and type 2 or other) aged
$12 years in Gloucestershire.
Gloucestershire contains a mixed rural
andurban, predominantlywhiteCaucasian
population (15). The Retinal Screening
Program invites eligible patients with dia-
betes aged$12years to attend aDRscreen-
ing clinic in one of 86 locations, where
specialist staff take a history,measure visual
acuity using Early Treatment Diabetic Ret-
inopathy Study (ETDRS) logMAR charts,
and take digital color retinal photographs
of two standard 458 ﬁelds (macula and disc
centered) per eye after dilation of the pu-
pils. Trained assessors in a central location
grade the presence and severity of DR
using a multilevel, internally and externally
quality-assured reading process that meets
national recommendations. For these anal-
yses, we included patients with at least
three annual graded image sets, the ﬁrst
two of which have either no retinopathy
or only background (mild nonproliferative
DR [NPDR]) in one or both eyes. Back-
ground (equivalent to ETDRS mild
NPDR) was deﬁned using the R1M0 cate-
gory in the English NHS Diabetic Eye
Screening Program, namely: presence
of microaneurysm(s), hemorrhage, or exu-
date, but having none of the features (16)
indicating referral to an ophthalmologist
for STDR, such as features of preprolifera-
tive (moderate to severe NPDR) or prolifer-
ative DR or photographic markers of
diabetic maculopathy.
The criteria used for grading in the
Gloucestershire Diabetic Eye Screening
Program and the relationship to the ETDRS
severity scale (17) are described below:
R0 level identiﬁes no detected DR
(equivalent to ETDRS level 10).
R1 level (mild NPDR or background
DR) identiﬁes a minimum of at least the
presence of one microaneurysm and/or
retinal hemorrhage, equivalent to ETDRS
levels 14–35. This is the deﬁnition used
by the NHS Diabetic Eye Screening Pro-
gram, and it is not possible to identify
those with ETDRS levels 14 and 15. How-
ever, the numbers of patients who would
have hemorrhages alone would be very
small.
R2 level (moderate to severe NPDR or
preproliferative DR) identiﬁes the pres-
ence of multiple deep, round, or blot
hemorrhages and/or deﬁnite intraretinal
microvascular abnormality and/or venous
beading and/or reduplication, equivalent
to levels 43–53 on the ETDRS scale.
R3 level (proliferative DR) indicates
the presence of proliferative DR (includ-
ing ﬁbrous proliferation), equivalent to a
minimum of ETDRS level 61.
M1 (maculopathy) identiﬁes the pres-
ence of two-dimensional photographic
markers of diabetic maculopathy, specif-
ically exudate within 1 disc diameter of
the center of the fovea, circinate, or group
of exudates within the macula or any
microaneurysm or hemorrhage within 1
disc diameter of the center of the fovea,
but only if associated with a best visual
acuity of worse than 0.3 logMAR (equiv-
alent to Snellen 6/12).
M0 describes the absence of any M1
features.
We report in this study on 14,554
patients with assessable images showing
either no DR (R0M0) or only mild NPDR
(R1M0) in one or both eyes at two
consecutive annual screenings (hereafter
referred to as baseline) and in whom there
was at least one further follow-up screen-
ing episode (Fig. 1).
Patients were categorized into groups
on the basis of the presence of retinopathy
in neither, one, or both eyes at each of the
two baseline screening episodes. Patients
with unassessable images, with any evi-
dence of previous laser treatment or with
features of STDR at either baseline screen-
ing event were excluded. STDR was de-
ﬁned by the presence of any R2 (moderate
to severe NPDR), R3 (proliferative DR), or
M1 (maculopathy) in either eye. Fig. 2
shows the possible grading in the two
eyes at the two screening episodes and
the resultant categorization groups. Pa-
tients were then followed until such
time as they developed features of STDR
or until the end of the study period.
We performed survival analysis, de-
ﬁning the time to event as the time from
the second screening to the development
of STDR at a subsequent screening epi-
sode; hence this was interval-censored.
Speciﬁcally, for those people who did not
develop STDR, the time to event was right
censored at the date of the last screening,
and for those people who developed
STDR, the data were left censored at the
date of the last screening at which no
STDR was found and with event time at
the date of the image set when STDR was
found. Data were plotted using Kaplan-
Meier estimates to show the cumulative
percentage of patients who developed
STDR. We ﬁtted Cox proportional haz-
ards models to estimate hazard ratios
(HRs). We examined parametric models
(g, Weibull, log logistic, logistic, and ex-
ponential) that were used to estimate the
proportion of patients expected to have
STDR at 1, 2, 3, 5, and 10 years after base-
line. The parametric model with the best
ﬁt (log logistic) was chosen using Akaike
information criterion to optimize the ﬁt of
the model. Proportions were compared
using x2 tests and continuous data be-
tween groups with ANOVA. We per-
formed analyses with SAS version 9.1.3
(SAS Institute) using Proc LIFEREG for
parametric modeling.
RESULTSdThere were 31,329 people
on the screening register between 2005 and
2010 with a median age of 63 years
(interquartile range 52–72). Of these, there
were 14,554 people who had two consec-
utive baseline screening episodes that both
demonstrated either no evidence of DR or
the presence of only mild NPDR in one or
both eyes who had at least one further
episode with gradable photographs.
The median age of the 14,554 patients in-
cluded as this cohort was 65 years (56–73).
The 16,775 patients who either did not
attend for two consecutive screenings or
were otherwise excluded were signiﬁcantly
younger (P, 0.0001), median age 60 years
(49–72).
There were 14,554 patients who
completed two consecutive annual
screenings with gradable photographs
showing no DR (R0M0) or mild NPDR
(R1M0) who had at least one further
episode with gradable photographs.
These were characterized into nine pos-
sible groups (Table 1). The least severe
group comprised 7,246 patients who
had no DR (R0M0) on both screening epi-
sodes, and the most severe baseline group
in this study population were 1,159 pa-
tients who had mild NPDR (R1M0) in
both eyes at both screenings. Of the
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remaining patients, 4,240 had mild
NPDR (R1M0) in one or both eyes but
only at one of these two screening epi-
sodes, 897 had mild NPDR (R1M0) in
only one eye at each screening episode,
and 1,012 had mild NPDR (R1M0) in
one eye at one episode but in both eyes
at the other screening.
The median period between the two
baseline screening episodes was 13.5
months (interquartile range 12.0–15.2),
and patients were then followed for a me-
dian 2.8 years (1.3–3.3). Themedian time
to ﬁrst follow-up screen in study after
baseline was 13.6 months (12.3–15.1),
to second screen after baseline was 26.6
months (24.9–28.3), to third 39.2
months (37.4–40.9), and to fourth was
51.6 months (50.8–52.1).
Of those excluded from the study,
2,458 had more severe retinopathy at
either ﬁrst or second baseline screening
episodes, 726 had previously treated DR,
949 had at least one unassessable image
set, and the rest had not attended three
screening episodes (Fig. 1).
There was no signiﬁcant difference
in the proportion of men and women
in the categories (P . 0.1). There were
differences (P , 0.001) between the age
groups in that those with mild NPDR in
both eyes at both screenings were youn-
ger at 63.0 years (SD 14.6) than the
groups who had either one or both eyes
without DR at one or both screening epi-
sodes. Patients in the three groups that
regressed were older.
Table 1 also shows the outcomes in
the nine baseline categories. Of 7,246
with no DR at both screenings (group
A), 120 subsequently progressed to
STDR, equivalent to an annual rate of
0.7%. Of 1,778 with no DR in either eye
at ﬁrst screening but mild NPDR in just
one eye at second screening (group D), 80
progressed to STDR, equivalent to an an-
nual rate of 1.9%. This was associated
with an HR of 2.9 (95% CI 2.2–3.8) com-
pared with those with no DR at both
screenings. Of 1,159 in the most severe
category (group I) with mild NPDR in
both eyes at both screenings, 299 pro-
gressed to STDR, equivalent to 11.0%
by 1 year and associated with an HR of
18.2 (14.7–22.5) compared with patients
with no DR at both screenings. Those in
higher risk groups were more likely to
progress to more serious DR (P, 0.001).
Fig. 2 shows the Kaplan-Meier plot of
time to detection of STDR from baseline.
There are clear differences between the
outcome of the groups and obviously in-
creased risk for patients who have mild
NPDR in both eyes at both annual screen-
ing events (group I) when compared with
those with no DR in either eye at both
screenings (group A).
CONCLUSIONSdUsing data from
only two sequential annual photographic
screening visits supported by a quality-
controlled grading system,we documented
signiﬁcant differences in the time to de-
velopment of retinopathy requiring refer-
ral to an ophthalmologist. As most annual
eye examinations in people with diabetes
in developed countries now include dig-
ital retinal photographs to monitor the
presence or absence of DR, these ﬁndings
suggest that photographs alone could be
used to differentiate levels of risk. This
implies that the interval for screening
could differ by level of risk. We believe
that this is the ﬁrst report identifying a
clear differentiation of risk to develop-
ment of STDR in patients who had either
no or only minimal background DR when
Figure 1dCohort identiﬁcation and inclusion/exclusion ﬂow chart.
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screened: a group normally considered to
be at very low and generally homogenous
risk. The difference in risk between groups
in this study is large. For example, we
demonstrate that a patient who was found
to have no retinopathy on the ﬁrst occasion
but mild NPDR in both eyes 1 year later
has a risk of subsequently developing
STDR approximately six times greater
than does a patient who has no DR on
both occasions. A patient who has bilateral
mildNPDR on both occasions has a risk for
subsequent development of STDR that
is 18.2 times higher than an individual
with no retinopathy at either screening
(Table 1).
Whereas the risk of progression in the
model by Vijan et al. (6) is based on the
Diabetic Retinopathy Study and ETDRS
reports, the risk we deﬁne in this study
is based entirely on two sets of digital im-
ages taken;1 year apart. With those two
seminal studies dating from the 1980s
and 1990s, the possibility exists that
with the passage of time and the changes
in treatment that accompany it, changes
will occur in the rate of progression of
disease.
This study does not compare risk of
referable retinopathy deﬁned by retinal
photographs with that deﬁned by clinical
criteria (e.g., time since diagnosis of di-
abetes, HbA1c, blood pressure). It does
not estimate risk for those in whom as-
sessment of DR by retinal photography
is not possible and who have to be
screened using slit-lamp biomicroscopy.
It does not test the number of images
required nor does it make explicit rec-
ommendations on the frequency or
cost-effectiveness of screening. Answer-
ing these questions requires further mod-
eling that our results could inform by
providing transition probabilities from
nonreferable to referable retinopathy.
Vijan et al. (18) developed a cost-utility
model for screening, with the conclusions
that for patients with good glycemic and
blood pressure control (that is, a lower
risk population), screening every 2 to 3
years would be appropriate while at the
same time advocating “close follow-up”
for the high-risk patient. They point out
that the costs associated with screening
low-risk individuals less frequently could
be better spent achieving close follow-up
of patients at higher risk.
Screening low-risk individuals too
frequently implies an inefﬁcient use of
limited health care resources. More efﬁ-
cient uses might include spending mon-
ey on strategies to bring retinal screening
to people with diabetes who are poor
attendees including, as we have shown in
this study, younger patients who tend
to be patients at high risk of retinopa-
thy (19), spending to prevent retinopathy
in people with diabetes, or spending
money elsewhere within the health care
system.
Two of the strengths of this study are
its size and that the population screened
accurately represents the underlying pop-
ulation with diabetes. Over 99% of pa-
tients with DM are eligible for screening
against the criteria of the English NHS
Diabetic Eye Screening Program (20). The
eligible population is increasing. In 2005,
there were 17,847 patients who were in-
vited for screening, but this ﬁgure had
risen to 27,520 by December 2010. The
average attendance ﬁgures following an
invitation was 74% in any one year, which
compares favorably to other populations
within the English NHS Diabetic Eye
Screening Program.
A recent report (21) from the Diabetic
Retinopathy Screening Service for Wales
described the incidence of any and refer-
able DR in people with type 2 diabetes
mellitus attending the annual screening
service inWales, whose ﬁrst screening epi-
sode indicated no evidence of retinopathy.
Their referable level is higher than in this
study, but the results are not directly com-
parable, as the deﬁnition of retinopathy
levels are not the same, and their study is
based on an initial screening episode,
Figure 2dTime to detection of STDR from second baseline screening with none or only mild
NPDR in one or both eyes. Signiﬁcant difference across groups (P , 0.0001).
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whereas this study population is not re-
stricted to ﬁrst screening episode.
This study evaluated people with type
1 or type 2 diabetes, most of whom were
of white northern European extraction. In
addition, the Gloucestershire screening
program has a robust quality-control pro-
gram of the imaging and grading pro-
cesses. Hence, to be generalizable, the
results would need to be validated in
other populations.
We propose that estimating risk in
this way can be useful in several ways,
either in discussions with patients during
eye examinations or in countries or in-
stitutions with systematic screening pro-
grams, to develop screening models to
allocate limited monies more efﬁciently
by varying the screening intervals de-
pending on an individual’s identiﬁed risk.
The results of this study may also help
to design and power clinical trials testing
interventions for DR. Many clinical trials
require a three-step progression on the
ETDRS severity scale. This is equivalent to
the progression from R1 mild NPDR to R2
moderate to severe NPDR in this study. If
patients were selected who had bilateral
mild NPDR on two consecutive screening
appointments, we have demonstrated an
overall progression to sight threatening DR
in 29% after 3 years and 40.4% after 5
years.
This risk estimator essentially helps
remove the requirement for complex
clinical-based data, as even if none of these
are taken into account, we can differenti-
ate risk by 18:1. We believe that this is the
ﬁrst report identifying a clear differentia-
tion of risk to development of STDR in
patients who had either no or only min-
imal background DR when screened: a
group normally considered to be at very
low and generally homogenous risk.
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